Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Imatinib Mesylate 71Sunitinib 31regorafenib 17nilotinib 15ripretinib 13avapritinib 7Laparoscopy 5Ipilimumab 5Dasatinib 5spartalizumab 4CTLA-4 Antigen 4Blood Specimen Collection 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Oxaliplatin 3Observation 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Biopsy 3Bevacizumab 3trametinib 2tanespimycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × TAS-116 × Sarcoma × Clear all
NCT05245968 2026-01-20

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Taiho Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
78 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡